ACCELERATE
JTC 2024 TRANSCAN-3Functional precision medicine platform for the treatment of pancreatic cancer
3 countries
3 funders
4 participants
Funded Projects
Explore TRANSCAN-funded research projects across calls, phases, cancer types, countries and funding organisations.
Funded Research Output
Browse the catalogue of projects funded through TRANSCAN joint transnational calls.
Combine scientific and programme filters to explore projects by cancer type, phase, call, country and funding organisation.
Projects list
Search and combine filters across the TRANSCAN project portfolio.
Showing 141 of 141 projects
BePrepared
JTC 2024 TRANSCAN-3Building an ex vivo complex tumour microenvironment platform for development of combination therapies and drug resistance studies in head neck cancer
4 countries
3 funders
5 participants
DOPPLER-LC
JTC 2024 TRANSCAN-3Development Of Patient-derived organoid PLatform for Evading Resistances in Lung Cancer
3 countries
2 funders
5 participants
GLIO-COMBO
JTC 2024 TRANSCAN-3Targeting tumor heterogeneity in pediatric high-grade gliomas
3 countries
3 funders
4 participants
HAVOC
JTC 2024 TRANSCAN-3Human avatar on chip for advancing personalized cancer therapies by integrating vascular and immune components in a Tumor-on-Chip model
3 countries
2 funders
3 participants
ioAVATAR
JTC 2024 TRANSCAN-3Immune oncology Drug Discovery & Decision - Advanced ex Vivo Approach To Accelerate Response prediction for combined therapies in ovarian cancer
4 countries
4 funders
5 participants
LUNGOIDS
JTC 2024 TRANSCAN-3Subtype-specific Lung Cancer Organoids based on artificial ECM for Precision Oncology: Closing the Gap Between Preclinical Models and Patient Care
3 countries
4 funders
4 participants
MELANOLOCK
JTC 2024 TRANSCAN-3Tackling resistance to immunotherapy in advanced melanomas through the inhibition of oncomiRs by Locked Nucleic Acids
3 countries
3 funders
4 participants
METRICs
JTC 2024 TRANSCAN-3Metabolism/Metagenomics-based strategies for sensitization to Radio- and Immuno- therapy Combinations.
7 countries
7 funders
7 participants
PREDICT-BC
JTC 2024 TRANSCAN-3Patient-derived models for the Research and Evaluation of Discovery and Innovation in Combination Therapies for Biliary Cancer
4 countries
5 funders
6 participants
SARAH
JTC 2024 TRANSCAN-3Search for combinational therapy to target clonal haematopoiesis in solid malignancies
3 countries
3 funders
4 participants
SeqPerGlio
JTC 2024 TRANSCAN-3Intraoperative tumour sequencing for personalized loco-regional drug combination therapy against glioblastoma recurrences
4 countries
5 funders
6 participants
TITAN
JTC 2024 TRANSCAN-3Novel Cancer Therapy: Inducing Double-strand DNA Breaks to Foster Tumor Cell Death, Antigenicity and Immunotherapy Response in New Personalized Models
4 countries
4 funders
5 participants
TOSCANINI
JTC 2024 TRANSCAN-3TAD disruption and aberrant expression as leukemia metabolic vulnerabilities for novel combination therapy tests in a drug screening platform
5 countries
5 funders
7 participants
XPANTHER
JTC 2024 TRANSCAN-3Radiothermal-Driven Immune Activation to Tackle Pancreatic Hypoxic Tumors
3 countries
4 funders
5 participants
DC2M-TAEC
JTC 2023 TRANSCAN-3Detection, Classification, Characterization and Treatment Monitoring of Tumors by Accessible Epigenetic Classification
4 countries
3 funders
4 participants
DICE
JTC 2023 TRANSCAN-3Epigenomic regulation of cancer immunity by dietary intervention
5 countries
6 funders
6 participants
EPILUCAFS
JTC 2023 TRANSCAN-3Chronic stress and immunosuppression in lung cancer: focus on epigenetic drivers in cancer-associated fibroblasts
4 countries
5 funders
6 participants
EPILUNAR
JTC 2023 TRANSCAN-3Epigenomic Profiling of Liquid Biopsy and Immunotherapy Resistance in Lung Cancer
4 countries
4 funders
5 participants
EpiNanSarc
JTC 2023 TRANSCAN-3Sarcoma subtyping and stratification using genome-wide epigenetic profiling
5 countries
6 funders
7 participants
EPIPROPER
JTC 2023 TRANSCAN-3Identifying EPIgenetic determinants and biomarkers of drug resistance via characterization of PROspective PERsister cells
5 countries
5 funders
5 participants
EPI_T-ALL
JTC 2023 TRANSCAN-3Unveiling the Epigenetic Landscape and Therapeutic Implications of Epigenetic Modifiers in Human T-cell Leukemia Initiation and Progression
4 countries
4 funders
4 participants
EXPLORE-NB
JTC 2023 TRANSCAN-3Exploring the epigenetic neuroblastoma landscape to improve measurable disease monitoring, disease understanding and personalized treatment
5 countries
4 funders
6 participants
HYDRA
JTC 2023 TRANSCAN-3Charting the epigenomic trajectory of progression towards metastatic colorectal cancer
3 countries
4 funders
5 participants
REACH
JTC 2023 TRANSCAN-3Reversing Epitranscriptomic Alterations for CHemosensitization of Pancreatic Cancer
4 countries
5 funders
5 participants
REACTION
JTC 2023 TRANSCAN-3Deciphering Epigenetic Biomarkers to Identify Preleukemic Carriers at Risk
4 countries
5 funders
6 participants
SCIE-PANC
JTC 2023 TRANSCAN-3Stromal Compartment and Immune Epigenome spatial networks to counter therapy evasion in PANcreatic Cancer
6 countries
6 funders
6 participants
SPELCASTER
JTC 2023 TRANSCAN-3Standardized Profiling of Epigenetic Loci for decentralized ClAssification of Sinonasal Tumors and idEntification of therapy Response markers
5 countries
5 funders
6 participants
ANGELA
JTC 2022 TRANSCAN-3Early detection of esophageal squamous cell carcinoma with the Cytosponge coupled with molecular biomarkers and machine learning
4 countries
2 funders
5 participants
BileCanMet
JTC 2022 TRANSCAN-3Precision medicine in cholangiocarcinoma: accurate tools for early detection and identification of PRMT5 as a novel pharmacological target
4 countries
4 funders
5 participants
CAR4PDAC
JTC 2022 TRANSCAN-3Hijacking stroma antigens for CAR-T cell immunotherapy of PDAC
3 countries
3 funders
4 participants
iCC-Strat
JTC 2022 TRANSCAN-3Risk stratification and subtyping of intrahepatic cholangiocarcinoma for early detection of recurrence and response to immuno-therapy
4 countries
3 funders
4 participants
IdeaTMEHCC
JTC 2022 TRANSCAN-3Identification of therapeutic targets using HCC DErived organoid Augmented with TME components.
4 countries
3 funders
4 participants
MATTO-GBM
JTC 2022 TRANSCAN-3Multimodality Artificial intelligence open-source Tools for Radiation Treatment Optimization in patients with Glioblastoma
3 countries
4 funders
4 participants
NK-4-GBM
JTC 2022 TRANSCAN-3Metabolically optimised NK cell therapies for Glioblastoma
4 countries
5 funders
5 participants
PaCaNano
JTC 2022 TRANSCAN-3Development of a pancreatic cancer drug-nanocarrier system selectively targeting tumour cells and tumour stroma to overcome treatment failure
3 countries
3 funders
5 participants
PANC-P53
JTC 2022 TRANSCAN-3Innovative peptide- and RNA-based strategies to modulate p53 for pancreatic cancer therapy
3 countries
2 funders
3 participants
PLASTIG
JTC 2022 TRANSCAN-3Tackling tumor heterogeneity and PLASTIcity as resistance mechanisms in Glioblastoma
4 countries
3 funders
4 participants
PRECEDENCE
JTC 2022 TRANSCAN-3Genotype matched therapies in intrahepatic cholangiocarcinoma: a multi-pronged strategy for improving efficacy and combating resistance.
5 countries
4 funders
6 participants
ReachGLIO
JTC 2022 TRANSCAN-3Reaching the heterogeneous vascular landscape of glioblastoma with multifunctional nanomedicines.
6 countries
6 funders
7 participants
SIMMBAP
JTC 2022 TRANSCAN-3Systemic immunological determinants of tumor evolution and therapy response in BRCA-mutated pancreatic cancer
3 countries
3 funders
4 participants
T-Plex EAC
JTC 2022 TRANSCAN-3T-Plex-Capture: Isolation of neoantigen-specific CD8+ T cell receptors for patient-specific immunotherapy in esophageal adenocarcinoma (EAC)
3 countries
3 funders
4 participants
ANEMONE
JTC 2021 TRANSCAN-3The ANswer within the microEnvironment: Malignant pleural mesothelioma resistance to Old and NEw drugs
4 countries
5 funders
5 participants
BIALYMP
JTC 2021 TRANSCAN-3Bispecific antibodies in Lymphoma: Microenvironmental profiling to predict treatment response and uncover immunogenic resistance mechanisms
4 countries
4 funders
6 participants
CHRYSALIS
JTC 2021 TRANSCAN-3Characterization of stromal and innate lymphoid cell populations involved in immunotherapy resistance in High-Grade Serous Ovarian Cancer through multiOMICS analysis
3 countries
3 funders
3 participants
IMMOSCAN
JTC 2021 TRANSCAN-3The role of IMMune OSteoclasts in CANcer – Implications for therapy
4 countries
3 funders
5 participants
ImmuMet
JTC 2021 TRANSCAN-3Invigorating immunity against brain metastases in lung and breast cancer patients
4 countries
5 funders
5 participants
iParaCyts
JTC 2021 TRANSCAN-3Understanding and therapeutically exploiting the immunosuppressive paracrine signalling in the tumour microenvironment of metastatic lesions
5 countries
6 funders
6 participants
LipidMac
JTC 2021 TRANSCAN-3Exploiting lipid-laden macrophages to overcome resistance to cancer immunotherapy
3 countries
5 funders
4 participants
MAGNOLIA
JTC 2021 TRANSCAN-3MAppinG adaptatioN Of tripLe negative breast cancer microenvironments to ImmunotherApy
4 countries
5 funders
6 participants
PERIMMUNE
JTC 2021 TRANSCAN-3INTRAPERITONEAL IMMUNE MODULATION FOR COLORECTAL PERITONEAL METASTASES
5 countries
6 funders
6 participants
PIXEL
JTC 2021 TRANSCAN-3Profiling and functional analysis of the Immune environment of eXtramedullary leukemia rELapses
4 countries
5 funders
6 participants
PREDICO
JTC 2021 TRANSCAN-3Defining Predictive Immunedeterminants of response to neoadjuvant Chemoradiation in Oesophageal adenocarcinoma
3 countries
3 funders
4 participants
Pur-Ther
JTC 2021 TRANSCAN-3New immunotherapies targeting the key purinergic checkpoints in the tumor microenvironment
3 countries
4 funders
6 participants
RISEBrain
JTC 2021 TRANSCAN-3Reverting immune suppression to elicit brain metastasis control
5 countries
6 funders
6 participants
SmartCAR-T
JTC 2021 TRANSCAN-3SmartCAR-T - Reprogramming of the tumor microenvironment with modular engineered CAR-T cells to augment the efficacy of immunotherapy
5 countries
5 funders
6 participants
TALETE
JTC 2021 TRANSCAN-3TArgeting acute myeloid Leukemia immunosuppressive microEnvironment by combined IDO1 inhibiTion and PD-1 blockadE
5 countries
6 funders
6 participants
TANGERINE
JTC 2021 TRANSCAN-3Artificial-intelligence-based end-to-end prediction of cancer immunotherapy response
5 countries
6 funders
6 participants
TENACITY
JTC 2021 TRANSCAN-3TargEting the Nectin fAmily to boost Cancer ImmuniTY
4 countries
4 funders
6 participants
TRanSLIT
JTC 2021 TRANSCAN-3Targeting ROBOs and SLIT guidance cues in the immunosuppressive stromal context of pancreatic cancer (TRanSLIT)
4 countries
6 funders
6 participants
TumorOUT
JTC 2021 TRANSCAN-3Innovative mRNA vaccine against NSCLC: Designing a platform of targeted polymeric nanoparticles for efficient personalized therapy
4 countries
5 funders
6 participants
UCIPredict
JTC 2021 TRANSCAN-3Circulating tumour microenvironment components as Urothelial Cancer Immunotherapy Response Predictors.
4 countries
4 funders
4 participants
BRCAddict
JTC 2017 TRANSCAN-2BRCAddict – Harnessing BRCAness as a therapeutic target in high-risk pediatric solid tumors
5 countries
6 funders
7 participants
ERANET-PLL
JTC 2017 TRANSCAN-2Implementation of (epi)genetic and metabolic networks in the targeting of T-cell prolymphocytic leukemia
3 countries
4 funders
5 participants
Euro MDS
JTC 2017 TRANSCAN-2An integrated european platform to conduct translational studies in myelodysplastic syndromes based on the EuroBloodNet infrastructure
4 countries
5 funders
4 participants
EuroTCLym
JTC 2017 TRANSCAN-2Translational Research in Peripheral T-Cell Lymphomas: from characterization to novel targets
4 countries
5 funders
5 participants
LIQUIDHOPE
JTC 2017 TRANSCAN-2Advancing Liquid Biopsies for Monitoring and Personalized Treatment of Children with Neuroblastoma
6 countries
7 funders
6 participants
MOLCARUTUC
JTC 2017 TRANSCAN-2Comprehensive genomic characterization of upper urinary tract urothelial carcinoma and paired bladder recurrences
4 countries
5 funders
4 participants
NExT
JTC 2017 TRANSCAN-2Establishing an algorithm for the early diagnosis and follow-up of patients with pancreatic neuroendocrine tumors
5 countries
6 funders
6 participants
PMTR-pNET
JTC 2017 TRANSCAN-2Predictive models of therapy response in pancreatic neuroendocrine tumors
3 countries
4 funders
4 participants
PREDICt
JTC 2017 TRANSCAN-2Profiling radioREsistant Differentiated thyroId Cancer: genes, immunity, cancer stem cells and epithelial-mesenchymal transition
3 countries
3 funders
4 participants
Quant-ALL
JTC 2017 TRANSCAN-2Automated, absolute quantification of MRD in ALL patients by droplet microfluidics, single DNA copy barcoding and IG/TR amplicon NGS
3 countries
3 funders
5 participants
ROCSANbio
JTC 2017 TRANSCAN-2Anti-PD1 and Niraparib (PARPi) combination therapy in gynae carcinosarcoma: Identification of response-predictive biomarkers and resistance mechanisms
3 countries
4 funders
4 participants
TOPMESO
JTC 2017 TRANSCAN-2A TranslatiOnal Platform for de-orphaning malignant pleural MESOthelioma
3 countries
3 funders
3 participants
ABC-Cancer
JTC 2016 TRANSCAN-2Airborne Biomarkers for Colorectal Cancer
3 countries
3 funders
4 participants
BioEndoCar
JTC 2016 TRANSCAN-2Biomarkers for diagnosis and prognosis of endometrial carcinoma
5 countries
5 funders
6 participants
CLEARLY
JTC 2016 TRANSCAN-2Validation of multiparametric models and Circulating and imaging biomarkers to improve Lung cancer EARLY detection.
5 countries
6 funders
7 participants
ESCEND
JTC 2016 TRANSCAN-2Detection of Early esophageal cancer by near-infrared fluorescence molecular endoscopy
3 countries
3 funders
3 participants
GLIOMA-PRD
JTC 2016 TRANSCAN-2Multiparameric Analysis of the Evolution and Progression of Low-Grade Glioma (LGG)
3 countries
5 funders
4 participants
iMMunocell
JTC 2016 TRANSCAN-2Single-cell immunophenotypic and transcriptomic profiling for minimally-invasive detection of early multiple myeloma
4 countries
5 funders
4 participants
NIRBTEST
JTC 2016 TRANSCAN-2New strategies to detect cancers in carriers of mutations in RB1: blood tests based on tumor-educated platelets, or extracellular vesicles.
3 countries
4 funders
5 participants
NOVEL
JTC 2016 TRANSCAN-2Employing NGS technology for improved, non-invasive early detection, staging and prediction of progression in lymphoma patients
5 countries
6 funders
7 participants
PROLIPSY
JTC 2016 TRANSCAN-2Early Detection of Prostate Cancer by Liquid Biopsies
5 countries
6 funders
5 participants
PROSCANEXO
JTC 2016 TRANSCAN-2Exploitation of extracellular vesicles for precision diagnostics of prostate cancer
5 countries
6 funders
5 participants
R.E.ST.ING
JTC 2016 TRANSCAN-2Non-invasive prognostic markers for Resected Early-STage NSCLC: role of circulatING and exosomal miRNAs and free circulating DNA
3 countries
4 funders
3 participants
SCRAtCH
JTC 2016 TRANSCAN-2Microbiota-based screening of anal cancer in HIV-infected individuals
4 countries
5 funders
5 participants
THRuST
JTC 2016 TRANSCAN-2Early detection of relapses in stage II-III colon cancer patients by following a personalized molecular signature from a blood test: THRuST
4 countries
5 funders
6 participants
TRANSCALL-2
JTC 2016 TRANSCAN-2Integration of genetic biomarkers and early Minimal Residual Disease to improve risk stratification and cure in childhood Acute Lymphoblastic Leukemia
4 countries
5 funders
6 participants
DIgesT
JTC 2015 TRANSCAN-2Impact of Dietary Intervention on tumor immunity
6 countries
4 funders
6 participants
EPICA
JTC 2015 TRANSCAN-2Dual EPigenetic targeting and Immunotherapy to fight against Cancer
3 countries
3 funders
3 participants
HEPAMUT
JTC 2015 TRANSCAN-2Mutated neo-antigens in hepatocellular carcinoma
6 countries
6 funders
7 participants
IMMUNOGLIO
JTC 2015 TRANSCAN-2Deciphering immune response against glioblastoma to find new targets
3 countries
3 funders
5 participants
IMMUSPHINX
JTC 2015 TRANSCAN-2Targeting sphingolipid metabolism to improve anti-melanoma immune therapies
4 countries
4 funders
5 participants
Microther
JTC 2015 TRANSCAN-2Improving immunotherapy of solid tumors by targeting the immunosuppressive tumor microenvironment: from pre-clinical "proof-of-concept" to the development of phase I studies
5 countries
4 funders
5 participants
RE-VOLU-TION
JTC 2015 TRANSCAN-2pREdiction of niVOLUmab acTION in metastatic renal cancer patients: Treg function, tumoral access and NK interactions as predictive biomarkers of immunotherapy.
4 countries
3 funders
4 participants
ARREST
JTC 2014 TRANSCAN-2Approaching recurrence and resistance mechanisms in esophagogastric adenocarcinomas from the prospective MEMORI trial
4 countries
4 funders
5 participants
BeFIT
JTC 2014 TRANSCAN-2Patient-derived models for intratumour functional heterogeneity and its implications for personalized medicine
4 countries
4 funders
4 participants
CCE Breast
JTC 2014 TRANSCAN-2Clinical Impact of Intratumor heterogeneity in metastatic breast cancer
4 countries
4 funders
5 participants
CEVIR
JTC 2014 TRANSCAN-2Cancer evolution and identification of relapse-initiating cells.
4 countries
4 funders
5 participants
DRAMA
JTC 2014 TRANSCAN-2Defeating Recurrence and resistance in AML: Multigenomic Approaches to analyse heterogeneity
5 countries
5 funders
6 participants
FIRE-CLL
JTC 2014 TRANSCAN-2Fighting Resistance in CLL
6 countries
6 funders
7 participants
GCH-CLL
JTC 2014 TRANSCAN-2Genetic and cellular intratumor heterogeneity as predictor of chronic lymphocytic leukemia outcome and treatment resistance
5 countries
6 funders
7 participants
HetMet
JTC 2014 TRANSCAN-2Intratumour heterogeneity, clonal selection and metastatic propensity in breast cancer
4 countries
5 funders
4 participants
INTRACOLOR
JTC 2014 TRANSCAN-2Evolution of resistant clones to novel target-directed drugs in colorectal tumors. - A genetic and epigenetic study of intratumoral heterogeneity dynamics
4 countries
4 funders
6 participants
IntraMMclo
JTC 2014 TRANSCAN-2Multiple myeloma intra-clonal heterogeneity: evolution and implications of targeted therapy
4 countries
4 funders
4 participants
ITEM
JTC 2014 TRANSCAN-2Dissecting phenotypic heterogeneity of human melanoma: building a rationale for active immunotherapies overcoming immunologically-induced dedifferentiation.
4 countries
5 funders
4 participants
ONTHETRRAC
JTC 2014 TRANSCAN-2Overcoming Neuroblastoma Tumour HETerogeneity, Resistance and RecurrAnCe
4 countries
4 funders
5 participants
PROMETOV
JTC 2014 TRANSCAN-2Proteogenomic and targeted metabolomic analysis of ovarian cancer heterogeneity and its contribution to recurrence and therapy resistance.
6 countries
6 funders
7 participants
TACTIC
JTC 2014 TRANSCAN-2TArgeting Colon Tumor Initiating Cell heterogeneity
4 countries
4 funders
5 participants
TH4RESPONS
JTC 2014 TRANSCAN-2Clinical utility of tumour heterogeneity in triple negative breast cancer and high-grade serous ovarian carcinoma for prediction of therapy response
4 countries
4 funders
4 participants
TORPEDO
JTC 2014 TRANSCAN-2Targeting Of Resistance in PEDiatric Oncology (TORPEDO)
4 countries
4 funders
6 participants
ASAMET
JTC 2013 TRANSCAN-1A randomized, 2x2 biomarker prevention trial of low-dose aspirin and metformin in colon cancer patients
4 countries
4 funders
5 participants
ATRTPepVac
JTC 2013 TRANSCAN-1Exploiting the peptidome of atypical teratoid/rhabdoid tumors - characterization of novel tumor-associated antigens for immunotherapy in order to maintain long-term remissions
3 countries
3 funders
4 participants
Bio-PaC
JTC 2013 TRANSCAN-1Biomarkers of tumor recurrence in pancreatic cancer
3 countries
3 funders
5 participants
BREMIR
JTC 2013 TRANSCAN-1MicroRNAs methylation and expression profiling for identification of breast cancer patients at high risk to develop distant metastases
3 countries
3 funders
3 participants
DietINT
JTC 2013 TRANSCAN-1A randomized phase II study for tertiary prevention of squamocellular cancer of head and neck (SCCHN) with a dietary intervention
6 countries
6 funders
6 participants
FOCUS
JTC 2013 TRANSCAN-1Biomarkers related to folate-dependent one-carbon metabolism in CRC recurrence and survival
4 countries
5 funders
5 participants
GENMEL
JTC 2013 TRANSCAN-1Identification of genetic markers involved in development of metastases and second cancers in melanoma
5 countries
6 funders
5 participants
HIGHCARE
JTC 2013 TRANSCAN-1High resolution project on prognosis and CARE of cancer patients
7 countries
7 funders
7 participants
IMMUNOSCOR
JTC 2013 TRANSCAN-1Integrative cancer-immunology and Immunoscore for cancer classification and immunotherapies
5 countries
5 funders
6 participants
MetBreCS
JTC 2013 TRANSCAN-1A randomized placebo controlled phase II study with Metformin in metabolic-unbalanced breast cancer survivors at higher risk for recurrence
3 countries
4 funders
3 participants
EpiMARK
JTC 2012 TRANSCAN-1An integrated approach for epigenetic risk assessment and biomarker development for breast cancer in prospective cohorts / Identifying early epigenetic predictors of breast cancer risk and their etiology determinants
5 countries
6 funders
7 participants
FAMILIAL CANCER
JTC 2012 TRANSCAN-1Cancer prevention through improved familial risk assessment and gene discovery
3 countries
3 funders
3 participants
HLALOSS
JTC 2012 TRANSCAN-1New technologies for early detection of HLA loss leukemia relapse after allogeneic hematopoietic stem cell transplantation, and identification of relevant risk factors
4 countries
5 funders
6 participants
Ma.Tr.OC
JTC 2012 TRANSCAN-1Identification of molecular therapeutic targets and diagnostic/prognostic biomarkers for Malignant Transformation of Osteochondromas
6 countries
7 funders
6 participants
MesaCapp
JTC 2012 TRANSCAN-1Mesalamine for Colorectal Cancer Prevention Program in Lynch syndrome
5 countries
5 funders
6 participants
MetaboCCC
JTC 2012 TRANSCAN-1Metabolomic profiles throughout the continuum of colorectal cancer
5 countries
6 funders
5 participants
NanoEFEct
JTC 2012 TRANSCAN-1Nanoparticle-Enhanced molecular Fluorescence-Endoscopy for detection of early-stage colorectal adenocarcinomas
4 countries
4 funders
5 participants
PREDICT
JTC 2012 TRANSCAN-1Personalized prevention of colorectal neoplasia by use of genetic variability for the prediction of efficacy and toxicity of treatment with COX-2 inhibitors and aspirin
6 countries
6 funders
6 participants
TRANsIBCCS
JTC 2012 TRANSCAN-1Development of a Comprehensive Risk Prediction Model for BRCA1 and BRCA2 mutation carriers
6 countries
5 funders
7 participants
Triage-MDS
JTC 2012 TRANSCAN-1TRanslational Implementation of Genetic Evidence in the management of MDS
4 countries
4 funders
4 participants
Bio RaRE
JTC 2011 TRANSCAN-1K-RAS mutations and DNA repair function in NSCLC
3 countries
3 funders
5 participants
CTC-SCAN
JTC 2011 TRANSCAN-1Circulating Tumor Cells as Biomarker for Minimal Residual Disease in Prostate Cancer
5 countries
5 funders
5 participants
ET-FES
JTC 2011 TRANSCAN-1Early prediction of efficacy of endocrine therapy in breast cancer: pilot study and validation with 18F Fluoroestradiol (FES) PET/CT
4 countries
4 funders
5 participants
GRAN-T-MTC
JTC 2011 TRANSCAN-1Phase I clinical trial using a novel CCK-2/gastrin receptor-localizing radiolabelled peptide probe for personalized diagnosis and therapy of patiens with progressive or metastatic medullary thyroid carcinoma
6 countries
6 funders
7 participants
HAPLO-IMMUNE
JTC 2011 TRANSCAN-1Validation of immune biomarkers predictive of clinical outcome after HLA-haploidentical hematopoietic stem cell transplantation for acute leukemia
3 countries
3 funders
4 participants
ImPECT
JTC 2011 TRANSCAN-1Immune Cells as Predictors for Early Diagnosis and Chemotherapy Toxicity in Ovarian Cancer
3 countries
3 funders
3 participants
PROVABES
JTC 2011 TRANSCAN-1PROspective VAlidation of Biomarkers in Ewing Sarcoma for personalised translational medicine
6 countries
5 funders
7 participants
TRANSCALL
JTC 2011 TRANSCAN-1Validation of the impact of genetic aberrations and host genetic variation in childhood acute lymphoblastic leukemia for integration into clinical practice
5 countries
5 funders
7 participants
UGI1
JTC 2011 TRANSCAN-1CD3 and CD20 lymphocytes infiltration to predict chemosensitivity in patients with triple negative breast cancer
3 countries
3 funders
5 participants
VALPRAXIN
JTC 2011 TRANSCAN-1Validation of Aprataxin as a biomarker of response to Topoisomerase I inhibitors in cancer patient
3 countries
3 funders
5 participants
No projects match the selected filters.